Seeking Alpha
Special situations, deep value, growth, momentum
Profile| Send Message|
( followers)  

Russell Investments has posted its official list of companies set to join or leave the U.S. broad-market Russell 3000 Index and Russell Microcap Index when its U.S. equity indexes are fully reconstituted on June 22.

On the preliminary list, we would like to focus specifically on the U.S. Healthcare additions to the Russell 3000 in alphabetical order below. This is because many of these companies have a new drug, service, specific niche, or are on the ground floor of some biotechnology cancer treatment(s) or drug(s) that have real strong potential in the U.S. and possibly the EU. Each stock mentioned is a company that is currently relevant to the healthcare industry today and has one or several key developments in its pipeline over the last 3-6 months. Some of these companies have experienced large gains and have caught the eyes of the Russell index managers as future growth leaders and you should also be aware of them too.

Let's pick a few stocks that may see continued upside as funds acquire the float in these new additions to the Russell.

Here are a few company examples:

Anika Therapeutics (NASDAQ:ANIK) develops, manufactures and commercializes therapeutic products for tissue protection, healing, and repair. These products are based on hyaluronic acid, a naturally occurring, biocompatible polymer found throughout the body. The company offers aesthetic dermal fillers for the correction of facial wrinkles, advanced wound treatments, and regenerative tissue technology. The dermatological products are a small part of ANIK's revenue, as it mostly comes from treatments for osteoarthritis of the knee and other surgical aids. The company has great revenue and profitability projections and a pipeline of products that can produce real value down the road and is worth a look.

IMMUNOCELLULAR THERAPEUTICS (NYSEMKT:IMUC) is a clinical-stage biotechnology company, which focuses on developing new immune-based products to treat and diagnose cancer. Its cell-based vaccine technologies are primary platform technologies and commercial prospects will be heavily dependent on the outcome of the contemplated clinical trials for current lead vaccine product candidate. Its product pipeline includes peptide-based vaccines to target cancer stem cells, cellular immunotherapies to target cancer associated antigens, and monoclonal antibodies to diagnose and treat several different cancers. ImmunoCellular product candidates include ICT-107, CT-121, ICT-109, ICT-037, ICT-69 and CT-Diagnostic-SCLC. The company focuses on immunotherapy technologies to treat glioblastoma, and these applicable therapies to multiple other cancers such as pancreatic, colon and breast cancers. Its antibodies are designed to treat small cell lung cancer, pancreatic cancer, multiple myeloma and ovarian cancer.

Synergy Pharmaceuticals (NASDAQ:SGYP) is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal disorders and diseases. While its not a glamerous business, its product candidate is Plecanatide, a Guanylyl Cyclase C, receptor agonist to treat gastrointestinal disorders, primarily chronic constipation and constipation-predominant-irritable bowel syndrome.

COMPANYSYMBOLCOUNTRYINDUSTRY
ACADIA HEALTHCARE(NASDAQ:ACHC)United StatesHealth Care
AGENUS INC(NASDAQ:AGEN)United StatesHealth Care
ANIKA THERAPEUTICS INC United StatesHealth Care
BIODELIVERY SCIENCES(NASDAQ:BDSI)United StatesHealth Care
CORONADO BIOSCIENCES(NASDAQ:CNDO)United StatesHealth Care
CUMBERLAND PHARMACEUTICALS(NASDAQ:CPIX)United StatesHealth Care
DERMA SCIENCES(NASDAQ:DSCI)United StatesHealth Care
DISCOVERY LABORATORIES(DCSO)United StatesHealth Care
ENTEROMEDICS INC(NASDAQ:ETRM)United StatesHealth Care
IMMUNOCELLULAR THERAPEUTICS United StatesHealth Care
INTEGRAMED AMERICA INC(NASDAQ:INMD)United StatesHealth Care
MEDIWARE INFORMATION SYSTEMS(NASDAQ:MEDW)United StatesHealth Care
MERRIMACK PHARMACEUTICALS(NASDAQ:MACK)United StatesHealth Care
OMEROS CORP(NASDAQ:OMER)United StatesHealth Care
REPLIGEN CORP(NASDAQ:RGEN)United StatesHealth Care
REPROS THERAPEUTICS(NASDAQ:RPRX)United StatesHealth Care
ROCHESTER MEDICAL CORP(NASDAQ:ROCM)United StatesHealth Care
SUPERNUS PHARMACEUTICALS(NASDAQ:SUPN)United StatesHealth Care
SYNAGEVA BIOPHARMA(NASDAQ:GEVA)United StatesHealth Care
SYNERGY PHARMACEUTICALS United StatesHealth Care
THRESHOLD PHARMACEUTICALS(NASDAQ:THLD)United StatesHealth Care
UTAH MEDICAL PRODUCTS INC(NASDAQ:UTMD)United StatesHealth Care
VENTRUS BIOSCIENCES INC(VTUS)United StatesHealth Care
XOMA CORP(NASDAQ:XOMA)United StatesHealth Care

Source: Russell 3000 U.S. Healthcare Additions For June 2012

Additional disclosure: Editor may initiate a few other stocks listed here within 72 hours.